The discussions with top executives from producers both of original and generic versions of the main therapeutic medicines were along similar lines to the Director-General's earlier valuable dialogue with vaccine producers. As with the earlier discussions, the conversation was informal and off the record, to enable an open sharing of experiences focusing on practical solutions.

Participants agreed to keep in touch and to continue to share information, as work continues on a range of fronts to expand and diversify therapeutic production and distribution around the world.

The MC12 TRIPS Decision adopted on 17 June contains a commitment that, no later than six months from the date of its adoption, members will decide on its possible extension to cover the production and supply of COVID-19 diagnostics and therapeutics.




Problems viewing this page? If so, please contact [email protected] giving details of the operating system and web browser you are using.